about
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceEnhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic PeptidesEmerging strategies to deplete the HIV reservoirBioinformatics and HIV latency.Latency reversal and viral clearance to cure HIV-1.Developments in HIV-1 immunotherapy and therapeutic vaccination.Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells.Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cellsEradicating HIV-1 infection: seeking to clear a persistent pathogen.Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoirPrecise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral LatencyThe immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.Chemokine receptor modeling: an interdisciplinary approach to drug design.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Dilazep synergistically reactivates latent HIV-1 in latently infected cells.Inhibiting the HIV integration process: past, present, and the future.Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.Modulation of the strength and character of HIV-specific CD8+ T cell responses with heteroclitic peptides.A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene.Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor.Computer-aided design and discovery of protein-protein interaction inhibitors as agents for anti-HIV therapy.How Might We Cure HIV?HIV cure: knocking on the door.Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells.HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational ART.Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling
P2860
Q21090483-1FB28A26-2A80-4B9F-A242-277981780713Q26800123-AFFFFD79-3B63-4BBB-AF8A-7A42943B3342Q27023877-0C39964F-A229-4C9E-9163-79BEFA0223C7Q28081427-2DAD8D21-30A7-4B33-B727-046C4E808CB5Q30248766-A6FE54E0-94BB-4703-9DE4-2A47632E9475Q30364312-652A3F96-6590-47E3-B9CC-7FC83EA685FEQ33771155-16F87CFB-E9BD-47CF-B7DA-38B8A80CC5F3Q34870253-5ABA617A-281D-4E24-8A96-5458EBDE439AQ35111879-01888556-405F-4C22-B602-F47D91D0B8CEQ35252186-D3AF792E-59B5-4B7B-8A10-CA77568BF00EQ35586914-464E68AA-E005-4D57-B1DB-E39F990DEE4EQ35812943-147DFD0A-E8E5-408F-9575-D282D37FAE54Q36148964-8A623179-220A-41E7-A46A-271A9F6E355DQ36283854-88D8E9EA-A169-47EB-8AC8-B42CE88DF348Q36302615-1BA59B29-DF84-45B7-A2B5-978C2893A167Q37626634-3B71988D-1646-46DB-A86B-0863CF1172D5Q37651096-727168BA-81D6-4251-98AE-72ECC7C0D33EQ38172960-5029BB57-4EF9-4740-80C2-CFFBAE5AFC25Q38204866-74671093-0CF0-453A-86E5-C009F078D583Q39148809-2022ABD4-8B30-4E2C-8ED0-3AE26D176ED4Q39352071-F6BD6704-10FB-45AF-B760-D2C1B095B009Q39600778-E65B339F-CD59-4652-9E46-912CD3A4F603Q40047262-A3C642BD-9725-4FA0-A8E6-BB0C923615AEQ40054870-E47E012E-0347-4FB6-86FE-F9CBF68C6E52Q40205321-1B125EA5-B03F-46C9-A66B-8E9B8FA56503Q42144330-0B9EC2A9-4196-4B50-8469-0F1CDED2375DQ42225889-525E3269-9FB6-4AC7-BD5E-E40EEC283135Q42227337-C61E202F-0323-4827-A5F9-F805107F09C7Q42266102-9B3D44A7-DF4D-4871-80A0-29B2B5842865Q43564279-6ED3AD37-9FAD-46B3-82DF-18FDFD41E4BBQ47098415-0C28ED23-040C-464D-A709-BE7B6352FC03Q49990061-AB2A79D0-C4B4-48AF-BE0C-B3CE3EDD488AQ56000943-8D3312C8-C861-4DF8-8447-9E73D4F34AD9
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prospects for treatment of latent HIV.
@ast
Prospects for treatment of latent HIV.
@en
type
label
Prospects for treatment of latent HIV.
@ast
Prospects for treatment of latent HIV.
@en
prefLabel
Prospects for treatment of latent HIV.
@ast
Prospects for treatment of latent HIV.
@en
P2093
P2860
P356
P1476
Prospects for treatment of latent HIV.
@en
P2093
K M Barton
N Soriano-Sarabia
P2860
P2888
P356
10.1038/CLPT.2012.202
P407
P577
2012-10-10T00:00:00Z
P6179
1014674381